Cargando...
Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date
B cells in general and BAFF (B cell activating factor of the tumor necrosis factor [TNF] family) in particular have been primary targets of recent clinical trials in systemic lupus erythematosus (SLE). In 2011, belimumab, a monoclonal antibody against BAFF, became the first biologic agent approved f...
Guardado en:
| Publicado en: | Drug Des Devel Ther |
|---|---|
| Autores principales: | , , |
| Formato: | Artigo |
| Lenguaje: | Inglês |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5357079/ https://ncbi.nlm.nih.gov/pubmed/28331294 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S114552 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|